

**UNITED STATES SECURITIES  
AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the Month of June 2023**

**Commission File Number: 001-38281**

---

**PHAXIAM Therapeutics S.A.**

(Translation of registrant's name into English)

---

**60 Avenue Rockefeller  
69008 Lyon France**

(Address of principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F S**

**Form 40-F E**



### **INCORPORATION BY REFERENCE**

This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-3 (File Nos. [333-248953](#) and [333-259690](#)) and registration statements on Form S-8 (File Nos. [333-222673](#), [333-232670](#), [333-239429](#), [333-255900](#) and [333-265927](#)), of ERYTECH Pharma S.A. (“ERYTECH” or the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

**Press Release dated June 28, 2023**

On June 28, 2023, PHAXIAM Therapeutics S.A. issued a press release announcing the change of the ticker symbol of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and became effective on June 29, 2023.

The full text of the press release is attached as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

**EXHIBIT INDEX**

<b><u>Exhibit</u></b>	<b><u>Description</u></b>
99.1	Press Release dated June 28, 2023.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**PHAXIAM Therapeutics S.A.**

Date: June 30, 2023

By: /s/ Eric Soyer  
Name Eric Soyer  
Title: Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

## Phaxiam Therapeutics announces its new mnemonic code on Euronext and Nasdaq: PHXM

Lyon (France) and Cambridge (MA, US), June 28, 2023 - Phaxiam Therapeutics (Nasdaq & Euronext: FR0011471135), announces change of the mnemonic code of its share from ERYP to PHXM, following the merger between ERYTECH and PHERECYDES. The change has been notified by Euronext and will be effective from June 29, 2023.

- Company name: Phaxiam Therapeutics
- ISIN code: FR0011471135
- **Mnemonic: PHXM**
- Listing: Euronext Paris (Compartment C) and Nasdaq

### About PHAXIAM Therapeutics

PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: *Staphylococcus aureus*, *Escherichia coli* and *Pseudomonas aeruginosa*.

PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit [www.erytech.com](http://www.erytech.com)

### Contacts

**PHAXIAM**  
Eric Soyer  
COO & CFO

**NewCap**  
Mathilde Bohin / Louis-Victor Delouvrier  
Relations investisseurs  
Arthur Rouillé  
Relations Médias

+33 4 78 74 44 38  
[investors@erytech.com](mailto:investors@erytech.com)

+33 1 44 71 94 94  
[phaxiam@newcap.eu](mailto:phaxiam@newcap.eu)